Physician profile
Ryan K Wong
NPI 1922234798
$5,134.34
in general payments reported to CMS, 2019-2025
17 companies · $642 in 2025
The $642 reported for 2025 was more than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $693 · 2020: $184 · 2021: $418 · 2022: $1,441 · 2023: $1,366 · 2024: $391 · 2025: $642.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,398.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,398.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alimera Sciences, INC. | $1,838.74 | 2021-2024 | Iluvien, Yutiq |
| Novartis Pharmaceuticals Corporation | $547.59 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $527.59 | 2019-2025 | Eylea Hd, Eylea |
| Alcon Vision LLC | $435.43 | 2023 | Ngenuity, Constellation |
| Genentech USA, INC. | $340.03 | 2019-2024 | Vabysmo |
| Glaukos Corporation | $312.21 | 2020-2024 | Idose |
| Apellis Pharmaceuticals, INC. | $246.81 | 2023-2025 | Syfovre |
| Astellas Pharma US INC | $201.46 | 2023-2025 | Izervay |
| Mallinckrodt Hospital Products INC. | $145.81 | 2025 | Acthar |
| Bausch & Lomb Americas INC. | $131.55 | 2022-2025 | Xipere, Visudyne, Retisert |
| Aerie Pharmaceuticals, INC. | $117.76 | 2019 | |
| Abbvie INC. | $106.47 | 2022-2025 | Ozurdex |
| Eyepoint US, INC. | $87.43 | 2022 | |
| Genentech, INC. | $29.28 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $24.30 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $21.66 | 2019 | |
| Spark Therapeutics, INC. | $20.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Wong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.